-
Mashup Score: 7Analysis of immune‐related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors - 4 month(s) ago
Immune checkpoint inhibitors are becoming an increasingly common treatment for advanced gastrointestinal cancer, but the possibility of immune-related adverse events has raised concerns. This large r…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
This proof-of-concept study shows that automated profiling of radiographic scans through deep learning can provide orthogonal information independent of existing clinicopathological biomarkers, bringing the goal of precision immunotherapy for patients with NSCLC closer.
Source: www.thelancet.comCategories: Latest Headlines, Oncologists1Tweet-
SCI members and others have developed a deep-learning CT signature that successfully predicted survival in patients with #NSCLC treated with #ImmuneCheckpointInhibitors. https://t.co/7fzvelUpKB #immunotherapy @HwakeleeMD @JoelNealMD @MFGensheimer https://t.co/tAnTOxJFya
-
-
Mashup Score: 3Improving immune checkpoint inhibitors' anti-tumor response and minimizing side effects - 11 month(s) ago
Scientists at Tohoku University have discovered a novel approach that improves the efficacy of immune checkpoint blockade (ICB)—a novel form of cancer treatment utilizing immune checkpoint inhibitors (ICIs)—and minimizes the associated side effects. They demonstrated that using ICIs to target tumor-positive lymph nodes generates a robust anti-tumor response against both local and systemic…
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Improving #immunecheckpointinhibitors' anti-tumor response and minimizing side effects @tohoku_univ https://t.co/qJZikGRVbf
-
-
Mashup Score: 0Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors - 1 year(s) ago
Background: Immune checkpoint inhibitors (ICIs) have been proven to be very effective in the treatment of multiple cancers. They have a unique side-effect profile distinct from conventional chemotherapy that can manifest as immune-related adverse events (irAEs). With expanding ICI use, clinicians will increasingly encounter irAEs, and thus adequate physician knowledge on their recognition and…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New study by @AhmedBilalKhal2 @GCalderonMD @ShadiaJalal @gdurm provides insight into the knowledge gaps regarding #immunecheckpointinhibitors and #irAEs among physicians in various specialties: https://t.co/uJEdTIASap @IUMedSchool @IUCancerCenter #Immunotherapy https://t.co/PV8GpoVqsv
-
-
Mashup Score: 0
Recent data support incorporation of immune checkpoint inhibitors into the treatment armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) cancer. This practical review focuses on clinical trials that influenced US Food and Drug Administration approvals and treatment guidelines in esophagogastric cancer, including the impact of location, stage, histology, human…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP @DrDanielKing clinical review the use of #immunotherapy #immuneCheckpointInhibitors for the treatment of gastric and esophageal/GEJ cancer based on histology, CPS and HER2 status. ➡️ https://t.co/pyfUUMpFHB #esocsm #immunoonc https://t.co/aQU3pcrcGM
-
-
Mashup Score: 3Outcomes of Immune Checkpoint Inhibitor Administration in Hospitalized Patients With Solid Tumor Malignancies - 1 year(s) ago
PURPOSE: More oncologists desire to treat their patients with immune checkpoint inhibitors (ICIs) in the inpatient setting as their use has become more widespread for numerous oncologic indications. This is cost-prohibitive to patients and institutions because of high drug cost and lack of reimbursement in the inpatient setting. We sought to examine current practice of inpatient ICI…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Giving #ImmuneCheckpointInhibitors #ICI to acutely ill hospitalized pts with advanced solid tumor cancer was associated w/ HIGH costs & POOR outcomes (approx 40/80% died within 30/180 days). ➡️ https://t.co/Yp3Lsne0Oz #immunotherapy #immunoonc @AmiPatelMD https://t.co/Q0v8TWnXBl
-
-
Mashup Score: 3Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab - 1 year(s) ago
Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable responses to many patients with solid and haematological cancers. The high prices and increasing use of immune checkpoint inhibitors put considerable strain on health-care budgets globally. This financial strain could jeopardise patients’ access to these anti-cancer therapies. However, substantial evidence…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Personal View: Alternative #dosing strategies for #immunecheckpointinhibitors to improve #costeffectiveness: a special focus on #nivolumab and #pembrolizumab https://t.co/miiCbK3sun
-
-
Mashup Score: 0Immune-Related Adverse Events Among COVID-19–Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade - 2 year(s) ago
Background: Whether COVID-19 vaccination and the associated immune response increases susceptibility to immune-related adverse events (irAEs) among patients treated with immune checkpoint inhibition (ICI) remains unknown. Short-term follow-up can assess the safety of concurrent administration of the vaccine and ICI treatment. Methods: We conducted an electronic health record analysis of a cohort…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study by researchers at @MSKCancerCenter shows that #COVID19 vaccination during ICI therapy is safe and efficacious: https://t.co/5FwbIGtGfP #irAE #COVID19nCancer #ImmuneCheckpointInhibitors #immunotherapy #ImmunoOnc @adamjwidman @mini_kamboj @wolchokj https://t.co/H4FuYIxNEd
-
-
Mashup Score: 3Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study - 2 year(s) ago
Maintaining baseline immunosuppression before treatment with an immune checkpoint inhibitor in kidney transplant recipients might not affect expected efficacy and might reduce the risk of allograft rejection mediated by immune checkpoint inhibitors.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Also in our August issue: #ImmuneCheckpointInhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study https://t.co/WWXOB5B4RU #Immunotherapy
-
-
Mashup Score: 0Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition - 2 year(s) ago
Objectives Epigenomic alterations in cancer interact with the immune microenvironment to dictate tumour evolution and therapeutic response. We aimed to study the regulation of the tumour immune microenvironment through epigenetic alternate promoter use in gastric cancer and to expand our findings to other gastrointestinal tumours. Design Alternate promoter burden (APB) was quantified using a…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by @sundar__raghav et al on "Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition" via https://t.co/2wxk9noONc #ImmuneCheckpointInhibitors #ICIs #GITumours https://t.co/Lcp2KBngJE
-
NOW ONLINE The findings of this study could support clinicians in making decisions on #ImmuneCheckpointInhibitors therapy in patients with gastrointestinal cancer ➡️https://t.co/9KmYocKnmN https://t.co/dRUksA7TeW